FibroGen (FGEN)
(Delayed Data from NSDQ)
$0.42 USD
0.00 (-0.95%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $0.41 -0.01 (-1.44%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
FibroGen, Inc [FGEN]
Reports for Purchase
Showing records 1 - 16 ( 16 total )
Company: FibroGen, Inc
Industry: Medical - Drugs
Company: FibroGen, Inc
Industry: Medical - Drugs
Company: FibroGen, Inc
Industry: Medical - Drugs
FGEN Q3 Takeaways and Thoughts on Roxa US Pathway; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ZHANG E
Company: FibroGen, Inc
Industry: Medical - Drugs
Company: FibroGen, Inc
Industry: Medical - Drugs
Roxa Receives EU Approval; Some Quick Thoughts on What''s Next
Provider: H.C. Wainwright & Co., Inc.
Analyst: ZHANG E
Company: FibroGen, Inc
Industry: Medical - Drugs
Awaiting Business Updates After Roxa CRL
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: FibroGen, Inc
Industry: Medical - Drugs
At its All-time Lows, What?s the Next Driver(s) for FGEN? 2Q21 Recap
Provider: H.C. Wainwright & Co., Inc.
Analyst: ZHANG E
Company: FibroGen, Inc
Industry: Medical - Drugs
Roxa Adcom Overwhelmingly Negative; US Approval Unlikely, In Our View
Provider: H.C. Wainwright & Co., Inc.
Analyst: ZHANG E
Company: FibroGen, Inc
Industry: Medical - Drugs
Roxa Safety Profile Concerns FDA; Adcom Opinions Will Be Critical
Provider: H.C. Wainwright & Co., Inc.
Analyst: ZHANG E
Company: FibroGen, Inc
Industry: Medical - Drugs
EU Positive CHMP Opinion on Roxadustat; Awaiting US Adcom on July 15
Provider: H.C. Wainwright & Co., Inc.
Analyst: ZHANG E
Company: FibroGen, Inc
Industry: Medical - Drugs
Quick Thoughts on Upcoming Roxa Adcom and ex-US Market; 1Q21 Recap
Provider: H.C. Wainwright & Co., Inc.
Analyst: ZHANG E
Company: FibroGen, Inc
Industry: Medical - Drugs
Latest Disclosure of MACE Analyses Disappointing; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ZHANG E
Company: FibroGen, Inc
Industry: Medical - Drugs
Uncertainty Increased with Surprising Adcom Request; Roxa US Launch Further Delayed; 4Q20 Recap
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: FibroGen, Inc
Industry: Medical - Drugs
Two Positive Differentiators for Roxa vs Competitor Support Ongoing (+) View
Provider: Jefferies & Company
Analyst: Research Department
Company: FibroGen, Inc
Industry: Medical - Drugs
As Competitor Fades with Inferior MACE, Roxa Becomes a Dominant Leader in HIF class
Provider: Stifel Nicolaus Co., Inc.
Analyst: SAMIMY A
Company: FibroGen, Inc
Industry: Medical - Drugs
Will Roxadustat Replace ESAs? Initiating Coverage of FibroGen With a Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
|